|
Steve joined KAI in March 2005. Prior to KAI, Steve held senior research leadership positions at Chiron Corporation and Thios Pharmaceuticals. He led multiple research programs at all stages from target identification to IND filing. Between 1994 and 2004, Steve held escalating positions at Chiron Corporation, most recently serving as Program Head of the kinase inhibitor program and member of the Research Management Team. At Chiron Steve was responsible for the evaluation of all new biological targets. As Chiron's Director of Lead Optimization Biology, he led all hit-to-lead projects and advanced many of these into full-scale lead optimization. Subsequently, as head of Chiron's kinase inhibitor program he oversaw kinase inhibitor research and personally led the identification of Advanced Pre-clinical Candidates (APCs) for cancer indications as well as heading the outlicensing of a pre-clinical program in diabetes and neurodegeneration. In 2004, Steve joined Thios Pharmaceuticals as Vice President of Research, where he led efforts targeting biological sulfation, primarily for the treatment of inflammation. Steve directed the identification of the first lead series for inhibition of a sulfotransferase and his research group advanced two therapeutic antibodies to the point of humanization. In these roles Steve also managed the identification and evaluation of pharmacogenomic technologies that can accelerate the research to development transition and support both indication and patient selection, as well as effective biomarker strategies. Dr. Harrison holds a Ph.D. in Molecular Biology and an M.A. and B.A. in Biochemistry, all from the University of Cambridge, England. He is the author of numerous scientific publications and an inventor on nine issued U.S. patents. | 